Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Totally 60 subjects will be included in the study. The present study was aimed to observe and
evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated
with adjuvant chemotherapy after breast cancer surgery. The primary endpoint was 6 months of
cardiac safety. Secondary endpoints included 3 months of cardiac safety, adverse events (AE),
severe adverse events (SAE), and DFS.